Aurinia Pharmaceuticals Inc (AUPH) Stock Rating Reaffirmed by Cantor Fitzgerald
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “buy” rating reissued by equities researchers at Cantor Fitzgerald in a research note issued on Monday. They presently have a $14.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 131.79% from the stock’s previous close.
AUPH has been the topic of several other reports. Vetr cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price target on the stock. in a report on Monday, July 31st. Seaport Global Securities restated a “buy” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Tuesday, August 15th. Finally, BidaskClub cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $10.15.
Shares of Aurinia Pharmaceuticals (AUPH) traded down 1.79% on Monday, hitting $6.04. The company had a trading volume of 1,693,500 shares. The company’s market cap is $504.25 million. Aurinia Pharmaceuticals has a 12-month low of $2.02 and a 12-month high of $10.54. The company has a 50 day moving average of $6.44 and a 200-day moving average of $6.52.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The business had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, analysts forecast that Aurinia Pharmaceuticals will post ($1.01) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Aurinia Pharmaceuticals Inc (AUPH) Stock Rating Reaffirmed by Cantor Fitzgerald” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/aurinia-pharmaceuticals-inc-auph-stock-rating-reaffirmed-by-cantor-fitzgerald.html.
Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its stake in shares of Aurinia Pharmaceuticals by 0.3% in the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock valued at $35,969,000 after purchasing an additional 19,200 shares during the last quarter. Vivo Capital LLC lifted its stake in shares of Aurinia Pharmaceuticals by 68.9% in the 2nd quarter. Vivo Capital LLC now owns 1,013,149 shares of the biotechnology company’s stock valued at $6,211,000 after purchasing an additional 413,149 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 357.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after purchasing an additional 684,816 shares during the last quarter. Balyasny Asset Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 66.7% in the 2nd quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $3,065,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of Aurinia Pharmaceuticals by 11,061.7% in the 1st quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock valued at $3,273,000 after purchasing an additional 442,138 shares during the last quarter. 27.76% of the stock is owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.